Liver Metastasis Of Breast Cancer Clinical Treatment Strategies Discussed

Breast cancer spread to the liver are associated with a poor prognosis, here we collected the data of 176 breast cancer patients with liver metastasis, and analysed the disease character and the efficacy of different treatment methods and their clinical prognosis.The study demonstrate the number of axillary lymph node metastasis and primary tumor size and tumor stage have close relation with the prognosis of the patients who had liver metastasis,and futher study results showed the patients with axillary lymph node metastasis positive and with primary tumor size≥T2 and with II to IV stage disease have liver metastasis easier. The chemotherapy is the most important salvage method for the braest cancer patients with liver metastasis, our results proved the combination regimen has higher clinical response than single drug, the regimen including paclitaxol or navelbine can obstain higher reponse rate. Our study also found endocrine agents such as progestogen and the third generation aromatase inhibiitors can produce the similar clinica response rate to the chemotherapy for the patients with estrogen recepter positive, but the adverse effect related to drugs always be less than chemothapy agents, and endocrine agents can instead of the chemothapy when the patients can not bear the severe toxic effect related to the chemotherapy. Herceptin is a humanised monoclonal antibody directed against the human epidermal growth factor-2 (Her-2) protein, Her-2 overexpression is associated with short survival in breast cancer. Our data show Herceptin used to the liver metastasic patients with Her-2 overexpression is effective as a single agent and in combination with chemotherpy, so Herceptin should become the important choice for liver metastasic patients with Her-2 overexpression in breast cancer. Intra-hepatic artery infusion chemotherpy and embolism was another treatment mothod for liver metastatic tumor, our study results showed this method can achieve better clinical response than the standard chemotherapy for the patients with liver metastatic diease in breast cancer, but when and how to choose it is still uncertain. In addition to the above mentioned, our data also revealed that the major factors influenced on the patents' progonosis was the numbers of metastatic organs and diease severe extent.